Embedded Files
FOCUSED PIPELINE ENTERING THE CLINIC
Our lead program, CFB-001, targets CIPN in patients receiving platinum based chemotherapy. We are building a focused pipeline of neuroprotective and restorative candidates for peripheral neuropathies.
LEAD PROGRAM
CIPN in platinum based chemotherapy; stage: pIND submission done Q1 2026. Phase 1b/2a planning.
FOLLOW-ON OPPORTUNITIES
Expansion into additional chemotherapies including taxanes and vinca alkaloids.
Expansion into other peripheral neuropathies including Diabetic, Radiation, and Compression Neuropathies.
COOL FLAME BIO DEVELOPMENT PIPELINE AND KEY PROGRAMS
CIPN
Initial market introduction in platinum class chemo (largest offender)
Follow on introduction in taxane class chemo
Multiple Human PoC Case Studies with clinical signal
Anticipate Phase 1b/2a studies start in CIPN 2H 2026*
*Assumes 1H 2026 funding
Diabetic Neuropathy
Diabetic Neuropathy is also based on mitochondrial dysfunction and oxidative stress
Stabilized mitochondria in diabetic neuropathy alleviates the root initiating cause symptoms
Follow on market introduction – 10x larger market than CIPN
Multiple Human PoC Case Studies with clinical signal
Report abuse